Viral enzyme inhibitor drug
Cellular receptor inhibitor drug
Ans. A. Viral enzyme inhibitor drug
Explanation: Vertical transmission of HIV 1 presents as Oral thrush, interstitial pneumonia, and severe lymphopenia during the first year of life. Maternal prophylaxis during pregnancy with the nucleoside analog zidovudine (ZDV, AZT), a retroviral reverse transcriptase inhibitor, reduces the risk of perinatal transmission by about two-thirds in HIVpositive women who have not previously received antiretroviral therapy. The CDC currently recommends a three-part regimen of zidovudine (ZDV). Antiretroviral treatment ideally should be initiated at 14 weeks of gestation and continued throughout pregnancy, followed by intravenous ZDV during labor, and oral administration of ZDV to the infant for six weeks postpartum.